The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

It is unknown if the cardioprotective and renal effects of glucagon‐like peptide‐1 receptor agonists are consistent across blood pressure (BP) categories in patients with type 2 diabetes and at high risk of cardiovascular events. Using data from the LEADER (9340 patients) and SUSTAIN 6 (3297 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Leiter, Lawrence A., Bain, Stephen C., Bhatt, Deepak L., Buse, John B., Mazer, C. David, Pratley, Richard E., Rasmussen, Søren, Ripa, Maria Sejersten, Vrazic, Hrvoje, Verma, Subodh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496251/
https://www.ncbi.nlm.nih.gov/pubmed/32372454
http://dx.doi.org/10.1111/dom.14079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496251/
https://www.ncbi.nlm.nih.gov/pubmed/32372454
http://dx.doi.org/10.1111/dom.14079

Ejemplares similares